/PRNewswire/ Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the successful completion of its acquisition of Antares Pharma, Inc..
First Quarter Revenue of $117.3 million, Representing a 32% YOY Increase, with GAAP Diluted Earnings per Share of $0.43 and Non-GAAP Diluted Earnings per Share.
Halozyme Reports First Quarter 2022 Results marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger.